Literature DB >> 8109950

In vitro activity of a new carbapenem antibiotic, BO-2727, with potent antipseudomonal activity.

S Nakagawa1, T Hashizume, K Matsuda, M Sanada, O Okamoto, H Fukatsu, N Tanaka.   

Abstract

BO-2727, a new 1-beta-methyl-carbapenem, was active at concentrations of 6.25 micrograms/ml or less against gram-positive and gram-negative bacteria, including some imipenem- and/or meropenem-resistant (MICs, > or = 12.5 micrograms/ml) Pseudomonas aeruginosa strains, against which it proved generally fourfold more active than imipenem and meropenem. BO-2727's antipseudomonal activity and its broad spectrum merit further investigation for clinical use by itself, since it was stable in the presence of renal dehydropeptidase I.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8109950      PMCID: PMC192804          DOI: 10.1128/AAC.37.12.2756

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I.

Authors:  K Ubukata; M Hikida; M Yoshida; K Nishiki; Y Furukawa; K Tashiro; M Konno; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 2.  Characterization of beta-lactamases.

Authors:  K Bush
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

3.  Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections.

Authors:  J P Quinn; E J Dudek; C A DiVincenzo; D A Lucks; S A Lerner
Journal:  J Infect Dis       Date:  1986-08       Impact factor: 5.226

4.  In vitro activity and beta-lactamase stability of a new carbapenem, SM-7338.

Authors:  H C Neu; A Novelli; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

5.  In vitro activity against aerobic and anaerobic gram-positive and gram-negative bacteria and beta-lactamase stability of RS-533, a novel carbapenem.

Authors:  H C Neu; N X Chin; G Saha; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

6.  In vitro antibacterial activity and beta-lactamase stability of the new carbapenem SM-7338.

Authors:  Y Sumita; M Inoue; S Mitsuhashi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

Review 7.  Thienamycin: development of imipenen-cilastatin.

Authors:  F M Kahan; H Kropp; J G Sundelof; J Birnbaum
Journal:  J Antimicrob Chemother       Date:  1983-12       Impact factor: 5.790

8.  MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities.

Authors:  H Kropp; J G Sundelof; J S Kahan; F M Kahan; J Birnbaum
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

9.  Antibacterial activities of a new stabilized thienamycin, N-formimidoyl thienamycin, in comparison with other antibiotics.

Authors:  T Kesado; T Hashizume; Y Asahi
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

10.  Cross-resistance to meropenem, cephems, and quinolones in Pseudomonas aeruginosa.

Authors:  N Masuda; S Ohya
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

View more
  14 in total

Review 1.  Comparative pharmacokinetics of the carbapenems: clinical implications.

Authors:  J W Mouton; D J Touzw; A M Horrevorts; A A Vinks
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

2.  In vitro activities of novel trans-3,5-disubstituted pyrrolidinylthio-1beta-methylcarbapenems with potent activities against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.

Authors:  R Nagano; K Shibata; Y Adachi; H Imamura; T Hashizume; H Morishima
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

3.  Antimicrobial activity of DU-6681a, a parent compound of novel oral carbapenem DZ-2640.

Authors:  M Tanaka; M Hohmura; T Nishi; K Sato; I Hayakawa
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

Review 4.  Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.

Authors:  J A Balfour; H M Bryson; R N Brogden
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

5.  In vitro and in vivo antibacterial activities of ER-35786, a new antipseudomonal carbapenem.

Authors:  F Ohba; M Nakamura-Kamijo; N Watanabe; K Katsu
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

6.  In vitro activities of aminomethyl-substituted analogs of novel tetrahydrofuranyl carbapenems.

Authors:  W J Weiss; P J Petersen; N V Jacobus; Y I Lin; P Bitha; R T Testa
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

7.  Quantitative correlation between susceptibility and OprJ production in NfxB mutants of Pseudomonas aeruginosa.

Authors:  N Masuda; N Gotoh; S Ohya; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

8.  Activity of carbapenem BMS-181139 against Pseudomonas aeruginosa is not dependent on porin protein D2.

Authors:  J C Fung-Tomc; E Gradelski; B Kolek; B Minassian; M Pucci; R E Kessler; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

9.  In vitro activity of BMS-181139, a new carbapenem with potent antipseudomonal activity.

Authors:  R E Kessler; J Fung-Tomc; B Kolek; B Minassian; E Huczko; E Gradelski; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

10.  Mechanism of enhanced antipseudomonal activity of BO-2727, a new injectable 1-beta-methyl carbapenem.

Authors:  N Hazumi; A Fuse; K Matsuda; T Hashizume; M Sanada
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.